

# GIPAM GmbH

**First published:** 10/10/2024

**Last updated:** 10/10/2024

Institution

Other

## Institution identification

### Institution ID

1000000324

---

### Institution countries



Germany



United Kingdom



United States

---

### Type of institution

Other

---

### Institution role

Data holder

Researcher

---

### Institution website

<https://www.gipam-health.com/>

---

### ENCePP partner

Yes

## Institution description

GIPAM is a global consultancy specialized in strategic market access and real-world evidence generation. We partner with companies using innovative approaches and tools to deliver work with transparency and integrity. Some specific capabilities are described below.

**Global Database Studies:** Our team has extensive experience conducting database studies in Germany, Italy, Spain, France, the Nordics, the UK, the US, and Japan, as well as multi-country studies. Also, data in many countries can be deterministically linked with other (typically primary or survey) data. In Germany, we are the only provider who can link claims with other data and have existing linked datasets for patients with multiple sclerosis, diabetes, and COPD that are available for analysis. We have experience in a broad range of studies, including epidemiologic studies, treatment patterns, comparative effectiveness, burden of illness, external control arms, and post-authorization safety studies (PASS).

**EVIGATOR:** We developed a unique software platform to support the development and implementation of evidence generation plans (EVIGATOR).

**ONCOCASE:** We offer proprietary software for German oncology practices (OncoCase) to generate a unique clinical oncology dataset in GER. This software also includes a mobile app for patient-reported outcome (PRO) data collection and is our standard platform to conduct medical chart reviews/prospective studies in various diseases across Europe.

**ANCHOR:** We have developed an AI-based literature review platform called ANCHOR, which includes a network meta-analysis (NMA) module using non-small cell lung cancer randomized clinical trials as a use case. Inclusion of other

diseases/study types can be done within weeks.

## Institution details

**Experience with collecting data directly from individual patients or respondents:**

Yes

---

**Interest in carrying out research that is funded by pharmaceutical companies:**

Yes

## Contact

Sabrina Mueller [sabrina.mueller@gipam-health.com](mailto:sabrina.mueller@gipam-health.com)

Main

[sabrina.mueller@gipam-health.com](mailto:sabrina.mueller@gipam-health.com)

Jason Simeone [jason.simeone@gipam-health.com](mailto:jason.simeone@gipam-health.com)

Alternate

[jason.simeone@gipam-health.com](mailto:jason.simeone@gipam-health.com)